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Abstract: 
Vaccination as defined by the WHO is “the administration of agent-specific, but safe, 
antigenic components that in vaccinated individuals can induce protective immunity 
against the corresponding infectious agent”. Regardless of their debated history, the 
standard vaccine approaches have been unsuccessful in providing vaccines for numerous 
infectious organisms. In the recent three decades, an enormous amount of immunological 
data was retrieved from clinical studies due to the advancement in human genome 
sequencing. These data are being deposited in databases and numerous scientific 
literatures. The development of several bioinformatics tools to analyze this rapidly 
increasing immunological databank has given rise to the field of immunoinformatics. This 
approach allows the selection of immunogenic residues from the pathogen genomes. The 
ideal residues could be industrialized as vaccine candidates to provide protective immune 
responses in the hosts. This methodology will significantly decrease the time and cost 
needed for the vaccine development.  This review focus on published articles that proposed 
as vaccine candidates through immunoinformatics analysis. The reviewed Published 
immunoinformatics studies provided vaccine peptide candidates against SARS-COV-2, 
which is based on functional and non-functional immunogenic proteins like open reading 
frame, spike protein, envelope protein and membranous protein. All of which are designed 
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by unique strategies like reverse vaccinology. Spike protein was the most common used 
target with different suggested B and T cell peptides due to the difference in methodology 
between the findings. 
Keywords: COVID-19 vaccine candidates, Peptides, Immunoinformatics. 
1. Introduction: 
In December 2019, a cluster of pneumonia cases, caused by a newly identified β-
coronavirus, occurred in Wuhan, China. However, there is no evidence so far that the origin 
of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) was from the 
seafood market. Rather, bats are the natural reservoir of a wide variety of CoVs, including 
SARS-CoV-like and MERS-CoV-like viruses [1-4]. The world health organization (WHO) 
officially named the disease as coronavirus disease 2019 (COVID-19). COVID-19 has 
spread throughout China and merged almost all worldwide. On 30 January 2020, WHO 
officially declared the COVID-19 epidemic as a public health emergency of international 
concern [5, 6]. The WHO reported more than five hundred southlands deaths and above ten 
million infections [7]. 
Identifying a "patient zero" is critical because it can help to curb further transmission; but 
in some infectious diseases such as COVID-19 the patients do not show  signs of being 
sick quickly enough to make their condition known before they may have passed it on[8].  
Interestingly, it was found that at least two different strains of SARS-CoV-2 had occurred 
a few months earlier before COVID-19 was officially reported [9]. A recently 
phyloepidemiologic analysis suggests that SARS-CoV-2 at the Huanan Seafood Market 
could have been imported from other places[10]. After sequencing and phylogenetic 
analysis, SARS-CoV-2 was considered as a member of β-CoVs [11, 12]. The CoVs family 
is a class of enveloped, positive-sense single-stranded RNA viruses having an extensive 
range of natural roots. These viruses can cause respiratory, enteric, hepatic, and neurologic 
diseases [13, 14]. The CoVs are genotypically and serologically divided into four 
subfamilies: α, β, γ, and δ-CoVs. Human CoV infections are caused by α- and β-
CoVs[13].Genome-wide phylogenetic analysis indicates that SARS-CoV-2 shares 79.5% 
and 50% sequence identity to SARS-CoV and MERS-CoV. However, there is 94.6% 
sequence identity between the seven conserved replicate domains in ORF1ab of SARS-
CoV-2 and SARS-CoV[12]. 
The SARS-CoV-2 is not only causing respiratory problems, it may also damage the heart, 
kidneys, liver and other organs; in Wuhan 14 to 30% of COVID-19 patients have lost their 
kidney function and now require either dialysis or kidney transplants. The SARS-CoV-2 
gains entry into humans by targeting ACE2 receptor that found on lung cells, which destroy 
human lungs through cytokine storms, this leads to hyper-inflammation, forcing the 
immune cells to destroy healthy cells. This is why some COVID-19 patients need intensive 
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care. The inflammatory chemicals released during COVID-19 infection cause the liver to 
produce proteins that defend the body from infections. However, these proteins can cause 
blood clotting, which can clog blood vessels in the heart and other organs; as a result, the 
organs are deprived from oxygen and nutrients which could ultimately lead to multi-organ 
failure and subsequent progression to acute lung injury, acute respiratory distress syndrome 
and often death. Although there are many vaccines candidates for COVID-19 [15-18], but 
no effective treatment or vaccine have been approved so far [19-21].  
It’s well known that most acute viral infections result in development of protective 
immunity [22, 23] and as a consequence, some of the T-cells will provide  immunological 
memory and protective immunity against these virus, as well as for SARS-CoV-2 
infection[24]. Nevertheless, the available data for human coronaviruses suggest the 
possibility that substantive adaptive immune responses can fail to occur [25-27] and robust 
protective immunity can fail to develop[28]. A failure to develop protective immunity 
could occur due to a T cell and/orantibody response of deficient durability, with the 
neutralizing antibody response being dependent on the CD4+ T cell response [27, 29].  
During these times of COVID-19 pandemic, understanding adaptive immunity to SARS-
CoV-2 is vital for vaccine design. Using HLA-I and HLA-II predicted peptide, circulating 
SARS-CoV-2 specific CD8+ and CD4+ T-cells were identified in 70% and 100% of 
COVID-19 convalescent patients, respectively[30]. 
In the last two decades, vaccine design researches have been made easier, precise and rapid 
by applying immunoinformatics.  This  requires the knowledge of disease pathogenesis, 
the immune system dynamics, database search , sequence comparison, structural modeling 
as well as motif analysis [31-33]. By using this advanced bioinformatics tools and 
databases, various peptide-based vaccines could be designed where the peptides act as 
ligands [62-64]. This approach has been used frequently in Zika virus [34], Dengue 
virus[35], HIV [36]SARS-CoV-2[15], and so many more [37-41] proposing promising 
peptides for designing vaccines. 
The SARS-CoV-2 genome size is about 30kb which encodes structural and non-structural 
proteins like other coronavirus strains; structural proteins include S protein (Spike), 
Eprotein (Envelope), M protein (Membrane), and N protein(Nucleocapsid)[42](Figure 
1).In this work , various published immunoinformatics studies [15, 43-47](last update 9 
June 2020) that provided vaccine candidates against SARS-COV-2 by reverse vaccinology 
are reviewed. 
2. Characteristic of Immunoformatics vaccine candidate: 
Immunoformatics epitope-based peptide vaccines are considered an alternative to 
conventional vaccines. Peptides used in the vaccines are designed computationally using 
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the reference sequences of amino acid of the antigenic proteins of targeted pathogens. 
These vaccines contain antigenic peptide epitopes with 20–30 amino acids having high 
immunogenicity. The recognition of the antigenic peptides by the immune system triggers 
the immune response by stimulating cytotoxic T cells or B cells, or both…… Nevertheless 
they generally have low anyginicity which require the use of adjuvant for improving the 
antigincity.  [48] 
The immune informatics tools used in this methodology focus on analyzing the 
presentation of peptides by MHC1 and MHC2 and the recognition by T cell and B cells. 
Furthermore, molecular dynamic and docking analysis are routinely used in this study. 
Finally, the   immune response simulation  to the constructed vaccine and in silico cloning 
in E Choli are becoming more popular  in the recent years.[49, 50] 
 A new analysis method in immunoinformatic which hold a great potential in the future is 
the use of in silico clinical trial for testing the immunology related interactions of drugs 
and procedure among several other uses. In silico clinical trials are very effective in 
refining the conventional clinical trials reducing the time and cost usually required for 
testing and validation of new therapies and procedures.[51] 
Immunoinformatics is a very cost effective in silico approach, which is a more stable and 
less costly method for developing precise multi- epitopes peptide vaccine. it require a  
shorter period of time when compared with  conventional laboratory techniques for 
development of vaccines.[52] 
3. Importance of epitope-based vaccine:  
Comparing to all other types of vaccines, epitope-based peptide vaccines consider with 
their low-cost production, easy modification in the structure, and safety, as the careful 
selection of subunit immunogenic component rather than the whole protein will most likely 
decrease the possible side effect of vaccination. Moreover the previous mentioned 
characteristic will exponentially accelerate the production of effective vaccine especially 
in the face of rapidly evolving pandemic infectious disease.[53]     
 Peptide based vaccine has shown a promising result in many preclinical and clinical trials. 
This is  more evident by the successful application of peptide based vaccine in disease like 
hepatitis C   and Cancers among other diseases.[54]  Furthermore, this type of vaccine 
shows an encouraging result as a preventive measure in cases of allergies as evident by the 
study done by Mark Larché who we reviewed clinical studies related to peptide 
immunotherapy targeting allergy to cats or to bee venom.[55] 
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4. Pattern of the characterized Epitope-Based Peptide Vaccine 
candidates against COVID-19 
Accelerate researches for vaccine design is critical, immunoinformatics and docking 
analysis studies has minimize a lot of time, efforts and cost to facilitates the procedure of 
vaccine design by identifying the binding site on a protein structure and modeling  the  3D 
structure of a complex from the free monomers[56, 57]. Other advantages are that 
experiments can be directed towards those residues and the functional effect of an 
interaction may be studied. Furthermore, molecular docking analysis may be focused on a 
specific interface patch[58]; and that is what in common in these studies[15, 43-47]by 
proposing epitope-based peptide vaccine candidates against SARS-COV-2 by 
immunoinformatics approach: 
The COVID-19 S glycoprotein is considered as a good  target for vaccine design   because 
it forms a characteristic crown of the virus and protrudes from the viral envelope, which is 
why it is easily recognized by the immune system[59]. The protein sequence of spike 
glycoprotein was explored thoroughly using multiple immunoinformatics-based tools, to 
identify various epitopes for effective vaccine. They used IEDB database [60] to identify 
linear B-cell epitopes particularly used BepiPred 2.0 prediction module [61]; while T-cell 
epitopes identification where conducted by multiple softwares such as   , ProPred [62] and 
ProPred-1[63] for the selection of MHC-I and MHC-II binding epitopes respectively . 
within previously identified B-cell epitopes, The spike glycoprotein was analyzed for B-
cell epitope identification in the IEDB database; they found 34linear B-cell epitopes with 
29 epitopes against MHC-I and 8 epitopes against MHC-II that can be possibly used for 
vaccine. Then they submitted the selected epitopes to VaxiJen2.0 server applying avirus as 
a target for evaluating the antigenic tendency [64]. Unfortunately, antigenic 
characterization in VaxiJen v.2.0 discarded 16 MHC-I epitopes out of 29 and 5 out of 8 
MHC-II epitopes as these seemed to be non-antigenic in nature.Their results pinpoint 13 
MHC-I (SQCVNLTTR, GVYYHKNNK, GKQGNFKNL, GIYQTSNFR, VSPTKLNDL, 
KIADYNYKL, KVGGNYNYL, EGFNCYFPL, GPKKSTNLV, SPRRARSVA, 
LGAENSVAY, FKNHTSPDV and DEDDSEPVL) and 3 MHC-II epitopes 
(IHVSGTNGT, VYYHKNNKS and FKNHTSPDV) within the spike glycoprotein of 
SARS-COV-2, and then they converted the antigenic epitopes into a single vaccine 
component, using(EAAAK)3 peptide linker. Finally, they run molecular docking between 
vaccine component and TLR-5 showed significant Atomic Contact Energy(ACE) value, 
which indicates spontaneous reactivity within the receptor-ligand complex.These epitopes 
are the ideal candidate to formulate a multi-epitope peptide vaccine; not only because of 
being selected from the linear B-cell epitopic region but also because of their antigenic 
properties was confirmed. 
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One of the advantages of this study, they used PatchDock server[65], which generates 
docking complex with negative ACE value for analysis. The ACE value of the docking 
complex was -259.62, which indicates spontaneous reactivity between the vaccine 
component and TLR-5[66]. As proper protein-protein docking regulates the cellular 
functions, the docking between the vaccine component and TLR-5 will activate immune 
cascades for destroying the viral antigens[67]. Furthermore, they converted the antigenic 
epitopes into a single vaccine component, using (EAAAK) peptide linker.  On the other 
hand, the limitation of this study, there is no population coverage analysis which that will 
draw attention due to the highly ongoing SARS-COV-2 mutations worldwide; but the key 
question,is these mutations have any actual functional effect on the pathogenicity of the 
virus. This is vital in our understanding of the infectious mechanisms and dictates the 
approach of vaccine development [68].To summarize, this immunoinformatics study 
predicted 13 MHC-I and 3 MHC-II epitopes within the spike glycoprotein of SARS-COV-
2, which may be good candidate for a multi-epitope peptide vaccine against SARS-COV-
2. 
In our previous study authored by  Abdelmageed et al,[15] Several techniques facilitating 
the combination of the immunoinformatics approach and comparative genomic approach 
were used in order to determine the potential peptides for designing T-cell epitope-based 
peptide vaccine using the envelope protein of COVID-19 as a target. The COVID-19 E 
protein is a small, integral membrane protein with critical functions such as pathogenesis, 
envelope formation, assembly and budding; alongside with its interactions with other 
COVID-19 proteins and host cell proteins (release of infectious particles after budding) 
[69, 70]. It’s well-known that the immune response of T-cell has the ability to a long-lasting 
memory response that B-cell, where the antigen can escape the antibody memory 
response[71]. based on this observation, and since SARS-CoV-2 specific T cells were 
found in patients recovered from these disease ,[72] a T epitope-based peptide vaccine will 
be  more effective against SARS-CoV-2.The whole genome of COVID-19 was analyzed 
by comparative genomic approach to determine the potential antigenic target [73]. Artemis 
Comparative Tool (ACT) [74] was used to analyze human Coronavirus (HCov-HKU1) 
reference sequence vs. Wuhan-Hu-1 COVID-19.The result revealed extensive mutation 
among the tested genomes. High rate of mutations in a terminal branch was observed, 
which are conformed in recent study by European Bioinformatics Institute [75]; despite of 
the high similarity between the genomes of the two strains. The four proteins were then 
analyzed by Vaxigen software to test the probability of antigenic proteins. Protein E was 
found to be the most antigenic gene with the highest probability.The binding affinity to 
MHC molecules was then evaluated. The protein reference sequence was submitted to 
IEDB MHC predication tool; a number of MHC class I and II related peptides were found 
promising candidates. Among which the peptides YVYSRVKNL, SLVKPSFYV and 
LAILTALRL show high potentiality for vaccine design with adequate world population 
coverage. T cell epitope-based peptide vaccine was designed for COVID-19 using 
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envelope protein as an immunogenic target. It is well known that peptides recognized with 
high number of HLA molecules are inducing immune response. Based on the above-
mentioned results and taking into consideration the high binding affinity to both MHC 
classes I and II, conservancy and population coverage, three peptides are strongly proposed 
to formulate a new vaccine against SARS-CoV-2. Among the primarily selected epitopes, 
the obtained results showed a very strong potential in the proposing 
epitopesYVYSRVKNL, SLVKPSFYV and LAILTALRL as a vaccine candidate due to its 
overall epitope conservancy, binding affinities and population coverage for the highest 
number of HLA molecules. 
Sarkar et al.[44]conducted an immunoinformatics study to develop potential vaccines 
against the SARS-CoV-2, by reverse vaccinology [76] and immunoinformatics approach. 
Four protein sequences, Nucleocapsid Phosphoprotein (N), Membrane Glycoprotein (M), 
ORF3a Protein (ORF3a) and Surface Glycoprotein (S) were selected for the possible 
vaccine design. Only two proteins (N and S), were recognized as potent antigens (0.709, 
0.534 respectively) and used in the next phases ofthe study. They used IEDB to generate 
epitopes, which revealed a good number of epitopes; however, they selected ten epitopes 
only based on the antigenicity scores with higher binding affinity. The B-cell epitopes were 
also selected based on their antigenicity and length (more than 10 amino acids). Upon 
continual computational experimentation, three possible vaccine constructs were 
candidates; one vaccine construct was selected as the best vaccine based on molecular 
docking study which is supposed to effectively act against the SARS-CoV-2. Three 
vaccines were constructed by molecular docking using the selected epitopes which are 
supposed to be directed to fight against the SARS-CoV-2. To construct the vaccines, and 
different linkers (EAAAK, GGGS, GPGPG and KK linkers) were used at their appropriate 
positions. PADRE sequence is an important sequence which was used in vaccine 
construction; the vaccine construct with the best result in the molecular docking, was 
considered as the best vaccine construct. According to docking results, it was found that 
CV-1 was the best constructed vaccine. CV-1 showed the best and lowest scores in the 
docking as well as in the MM-GBSA study by HawkDock server[77]. 
In another work done by Enayatkhani et al. [16] three proteins (N, ORF3a and M) were 
chosen to predict the potential immunogenic B-cell andT-cell epitopes and then validated 
using various immunoinformatics servers and softwares. They used the Rankpep server 
[78] which covers almost all HLA to predicted different epitopes from N, ORF3a and M 
proteins sequence according to HLA I and HLA II alleles. Antigenic epitopes with high 
binding affinity score were predicted that were selected for further analysis; while for the 
linear epitope prediction, the BepiPred server was employed. BepiPred analysis revealed 
several continuous predicted epitopes of N, ORF3aand M proteins. For cross-checking the 
predicted epitopes, the sequence of all three proteins was also predicted by Kolaskar & 
Tongaonkar Antigenicity [79]. The linear B-cell epitopes that are both cellular and humoral 
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immune responses are essential against coronaviruses infection. Finally, epitopes that were 
shared between B cell and T-cell were selected. 
The final vaccine was designed based on the elicitation humoral and cellular immune 
responses. Due to the low immunogenicity of the epitope, they chose epitope-rich domains 
to generate a more diverse and robust response [80]. Based on in silico analysis, 
five epitopes-rich domains including highly scored and shared epitopes between T and B-
cellepitopes were selected and joined to each other with a three AAA linker. Several 
evaluations for the candidate structural analysis and molecular docking and MD 
simulations study were done; which revealed stimulate both cellular and humoral 
immunity, NOM recombinant protein could be considered as a possible vaccine candidate 
against SARS-COV-2. We checked each epitope of all studied proteins among other 
studies with its corresponding protein and between other proteins; we didn’t find any 
overlapping (not even a partial) between epitopes; this could be due to each study was 
conducted by unique strategy. 
To conclude, our review revealed that, there are 6 published immunoinformatics papers 
that proposed the most promising B and T-cells epitopes for vaccine candidates against 
SARS-CoV-2. SARS-CoV-2 gains entry into humans by targeting ACE2 receptor that 
found on lung cells by S protein, which destroy human lungs through cytokine storms, this 
leads to hyper-inflammation, forcing the immune cells to destroy healthy cells[30]. 
Therefore, S protein is the main target of most vaccine studies with 31 T-cell epitopes and 
21 B-cell epitopes. It’s also clear that these studies proposed the most promising B and T-
cells epitopes for vaccine candidates against SARS-CoV-2 are coming from S protein 
studies due to the same above mentioned reason. N protein studies are the next with 6 T-
cell epitopes and 19 B-cell epitopes; followed by E protein studies with 3 T-cell epitopes; 
while M with8 B-cell epitopes and ORF3a proteins studies with 1 T-cell epitopes and 7 B-
cell epitopes, (Table 1-2; Figure 2). Due to lack of information about SARS-CoV-2, these 
studies are vital for vaccine development. The most promising peptides have been gathered 
in this article which acts as a platform for vaccine design against SARS-COV-2 after in 
vitro and in vivo validation. 
Summary of the reviewed papers result: 
In Tilocca et al. work SLVKPSFYV,LTALRLCAY for MHC1 and KPSFYVY, 
SRVKNLNS for MHC2 were predicted as good candidate among other possible choices. 
In Abraham Peele K. and colleagues work, final vaccine construct was composed of 425 
amino acids including the 50S ribosomal protein adjuvant. Molecular docking with TLR-
3 immune receptor and MD simulations confirmed stability of the binding pose of this 
vaccine. Only one peptide (ITLCFTLKR) was found as probable vaccine   candidate in the 
study done by Joshi et al. with 99.8% structural favorability as perRamachandran-plot 
analysis.  In addition to suitable range of IC50 and population coverage values. 
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In the work done by Saherobai and colleagues the Spike protein 
peptidesSQCVNLTTRTQLPPAYTNSFTRGVY andFTISVTTEI was predicted to have 
the highest binding affinity tothe B-Cells and MHC I HLA-B1503 allele respectively. 
Furthermore, TheNucleocapsid peptides KTFPPTEPK andRWYFYYLGTGPEAGLwere 
found to have the highest binding affinity to the MHC I HLA-A0202 allele. 
In the work done by   Vipul Kumar and ManojJena   The constructed vaccine from all the 
three SMN polyproteins was found to be a potent antigen with score 0.60, non-allergen 
with a score of -0.59, have a molecular weight of 38.8 KDa, PI of 9.92, and half-life inside 
the E.coli >10 hours . In Ahmed Rakib and colleagues’ study, the two following candidates 
peptides (WTAGAAAYY and GAAAYYVGY) were chosen as best candidate for MHC1. 
While in ZairaRehman and colleages study  , LFRKSN and SYGFQPT l were found to 
behighly B-cell antigenic peptides .while    CVADYSVLY and FTNVYADSF were found 
to display  affinity for maximum number of MHC-I alleles, and  YRLFRKSNL, 
VYAWNRKRIdisplayed affinity for maximum number of MHC-II alleles. The docking 
analysis revealed strong interactions of the chosen Tcell  epitopes  with MHC-I and MHC-
II alleles. As noticed from this work different approach lead to the choose of different 
peptide for the same immunogenic targets. 
 Table 1: Detected T-cells epitopes for vaccine candidates against COVID-19: 
protein's 
name 
T-cells Epitopes References  
S protein 
SQCVNLTTR; GVYYHKNNK; GKQGNFKNL; GIYQTSNFR; VSPTKLNDL; 
KIADYNYKL; KVGGNYNYL; EGFNCYFPL; GPKKSTNLV; SPRRARSVA; 
LGAENSVAY; FKNHTSPDV; DEDDSEPVL; IHVSGTNGT; VYYHKNNKS;  ; 
SVLNDILSR; GVLTESNKK; RLFRKSNLK; QIAPGQTGK; TSNFRVQPTESI; 
SNFRVQPTESIV; LLIVNNATNVVI; VVLSFELLHAPATVC; 
VVVLSFELLHAPATV; RVVVLSFELLHAPAT; GYQPYRVVVLSFELL; 
PYRVVVLSFELLHAP; QPYRVVVLSFELLHA; YRVVVLSFELLHAPA; 
TQLNRALTGIAVEQD; QLNRALTGIAVEQDK; WTAGAAAYY; GAAAYYVGY. 
[44-46] 
E protein YVYSRVKNL; SLVKPSFYV; LLVTLAILTALRLCA                    [15] 
 
N protein 
 
 
LIRQGTDYKHWP;  RLNQLESKMSGK; LNQLESKMSGKG; 
LDRLNQLESKMSPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQH
GKEDLKFPRGQGVPINTNSSPDDQIGYYRRATRR; IRGGDGK; 
HWPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDK 
DPNFKDQVILLNKHIDAYKTFPPTEPKK  
[16] 
ORF-7A 
protein 
ITLCFTLKR  [43] 
Table 2: Detected B-cells epitopes for vaccine candidates against COVID-19: 
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protein's name B-cells Epitopes References 
S protein 
LTPGDSSSGWTAG; VRQIAPGQTGKIAD; YQAGSTPCNGV;  
QTQTNSPRRARSV; ILPDPSKPSKRS; VVLSFELLHAPATVC;  
VVVLSFELLHAPATV; RVVVLSFELLHAPAT;  
GYQPYRVVVLSFELL; PYRVVVLSFELLHAP;                                                    [44, 45] 
QPYRVVVLSFELLHA; YRVVVLSFELLHAPA;  
TQLNRALTGIAVEQD; QLNRALTGIAVEQDK;  
WTAGAAAYY; GAAAYYVGY.  
M protein 
NGTITVEELKKLLEQW; AN; PLLESE; KLGASQRVAGDS; 
 LTWICLLQFA; LYIIKLIFLWLLWPVTLACFVLAAVY;                                        [16] 
AMACLVGLM;LSYFIASFR.  
N protein 
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGA 
RSKQRRPQGLPNNTAS; RIRGGDGKMKDL;  
TGPEAGLPYGANK;GTTLPKGFYAEGSRGGSQASSRSSSRS 
RNSSRNSTPGSSRGTSPARMAGNGGD;SKMSGKGQQQQGQ 
TVTKKSAAEASKKPRQKRTATKAYN; 
KTFPPTEPKKDKKKKADETQALPQRQKKQQ; 
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQR                             [16] 
RPQGLPNNTAS; QHGKEDLKFPRGQGVPINTNSSPDDQIG;  
RIRGGDGKMKDL; QFAPS; EVTPSGTWL; KLDDKDPNFK; 
KTFPPTEPKKDKKKKADETQALPQRQKKQQ; WFTALTQH;  
GQGVPIN;QIGYYRR; KHWPQIAQFAPSASAFF; YTGAIKL; 
 KDQVILLNKHIDAYKTF. 
ORF3a protein 
 
QGEIKDATPSDF; KIITLKKRWQL; QL; STQLSTDTGV;                                      [16] 
GWLIVGVALLAVFQS; SKGVHFVCNLLLLFVTVYSHLLLVAAG; YQLYST; 
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Figure 1:5′ and 3′ terminal sequences of the SARS-CoV-2genome. The gene order is 5′-
replicase ORF1ab-spike protein S-envelope (E)-membrane (M)-N-3′. ORF3ab, ORF6, 
ORF7ab, ORF8, ORF9ab, and ORF10 are located at the predicted positions shown in the 
picture. 1a, 1b, 3a, 3b, 6, 7a, 7b, 8, 9a, 9b, 10 in the picture represent different ORF genes. 
It also shows the post promising peptides in each protein that has been studied.  
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Figure 2: Statistical chart for the most promising B-cell and T-cells from the previous 
mentioned papers for vaccine candidates against SARS-COV-2 
5. In vitro verification and validation of the epitope-based peptidases vaccine; 
 In vitro validation of the proposed peptide vaccine is a necessary step to ensure it is 
efficacy and safety. This can be done in different platforms , but the most common one is 
the mouse, as in the study done by Agallou et al. who experimentally validate a multi-
epitope peptide vaccine from  four known Leishmania infantum proteins ( cysteine 
peptidase A (CPA), histone H1, KMP-11, and Leishmania eukaryotic initiation factor 
(LeIF) on BALB/c Mice.[81] 
6.  Conclusion: 
Up-to-date several vaccine candidates based on immunoinformatics studies   have been 
suggested. In this review   proposed vaccine candidates against SARS-COV-2 was 
predicted using the methodology of reverse vaccinology. Different immunogenic targets 
were used in these papers, which is based on structural and non-structural proteins. 
Furthermore, no overlap was noticed in the papers who assessed the same targets, probably 
due to the use of different bioinformatics tools for analysis. Spike protein seems to be the 
best immunogenic target for COVID-19 vaccine design, this can be further validated by 
the current and the future in vitro and in vivo studies. 
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